The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1

Article metrics

  • A Corrigendum to this article was published on 01 March 2006


The Vpr protein of HIV-1 functions as a vital accessory gene by regulating various cellular functions, including cell differentiation, apoptosis, nuclear factor of κB (NF-κB) suppression and cell-cycle arrest of the host cell. Several reports have indicated that Vpr complexes with the glucocorticoid receptor (GR), but it remains unclear whether the GR pathway is required for Vpr to function1. Here, we report that Vpr uses the GR pathway as a recruitment vehicle for the NF-κB co-activating protein, poly(ADP-ribose) polymerase-1 (PARP-1). The GR interaction with Vpr is both necessary and sufficient to facilitate this interaction by potentiating the formation of a Vpr–GR–PARP-1 complex. The recruitment of PARP-1 by the Vpr–GR complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-κB. The association of GR with PARP-1 is not observed with steroid (glucocorticoid) treatment, indicating that the GR association with PARP-1 is a gain of function that is solely attributed to HIV-1 Vpr. These data provide important insights into Vpr biology and its role in HIV pathogenesis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Vpr transcriptionally suppresses NF-κB through a pathway that does not require a functional glucocorticoid receptor.
Figure 2: Vpr interacts with PARP-1 and inhibits its nuclear localization through a GR interaction-dependent pathway.
Figure 3: The GR interaction with Vpr is both necessary and sufficient to recruit PARP-1.
Figure 4: Recruitment of PARP-1 to the Vpr–GR complex is necessary for Vpr-mediated transcriptional suppression of NF-κB.
Figure 5: The PARP-1–Vpr–GR interaction is relevant in vivo.

Accession codes




  1. 1

    Muthumani, K. et al. Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into the mechanism. Cell Death Differ. 12, 962–970 (2005).

  2. 2

    Gandhi, R. T. & Walker, B. D. Immunologic control of HIV-1. Annu. Rev. Med. 53, 149–172 (2002).

  3. 3

    Ho, D. D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).

  4. 4

    Xu, X. N. et al. Evasion of cytotoxic T lymphocyte (CTL) responses by Nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J. Exp. Med. 186, 7–16 (1997).

  5. 5

    Letvin, N. L. Progress in the development of an HIV-1 vaccine. Science 280, 1875–1880 (1998).

  6. 6

    Geleziunas, R. et al. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410, 834–838 (2001).

  7. 7

    Muthumani, K. et al. Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem. Biophys. Res. Commun. 304, 583–592 (2003).

  8. 8

    Levy, D. N. et al. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 91, 10873–10877 (1994).

  9. 9

    Levy, D. N., Refaeli, Y. & Weiner, D. B. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69, 1243–1252 (1995).

  10. 10

    Sherman, M. P. et al. HIV-1 vpr displays natural protein transducing properties: implications for viral pathogenesis. Virology 302, 95–105 (2002).

  11. 11

    Jowett, J. B. et al. Human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J. Virol. 69, 6304–6313 (1995).

  12. 12

    Ayyavoo, V. et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor κB. Nature Med. 3, 1117–1123 (1997).

  13. 13

    Stewart, S. A. et al. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol. 71, 5579–5592 (1997).

  14. 14

    Goh, W. C. et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med. 4, 65–71 (1998).

  15. 15

    Jacotot, E. et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J. Exp. Med. 193, 509–519 (2001).

  16. 16

    Muthumani, et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J. Biol. Chem. 277, 37820–37831 (2002).

  17. 17

    Muthumani, K. et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int. Immunol. 17, 103–116 (2005).

  18. 18

    de Noronha, C. M. et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294, 1105–1108 (2001).

  19. 19

    Muthumani, K. et al. HIV-1 viral protein-R (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo. Mol. Ther. 12, 910–921 (2005).

  20. 20

    Refaeli, Y., Levy, D. N. & Weiner, D. B. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc. Natl Acad. Sci. USA 92, 3621–3625 (1995).

  21. 21

    Kino, T. et al. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J. Exp. Med. 189, 51–62 (1999).

  22. 22

    Ramanathan, M. P. et al. Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling. J. Biol. Chem. 277, 47854–47860 (2002).

  23. 23

    Doppler, W. et al. Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5. Mol. Cell. Biol. 21, 3266–3279 (2001).

  24. 24

    Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-kappaB. Nature Rev. Mol. Cell Biol. 5, 392–401 (2004).

  25. 25

    Oliver, F.J. et al. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 18, 4446–4454 (1999).

  26. 26

    Hassa, P. O. et al. The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J. Biol. Chem. 276, 45588–45597 (2001).

  27. 27

    Chang, W. J. & Alvarez-Gonzalez, R. The sequence-specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J. Biol. Chem. 276, 47664–47670 (2001).

  28. 28

    Hassa, P. O. et al. The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J. Biol. Chem. 276, 45588–45897 (2001).

  29. 29

    Mahalingam, S. et al. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J. Virol. 71, 6339–6347 (1997).

  30. 30

    Arad, G. et al. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nature Med. 6, 414–421 (2000).

  31. 31

    Kim, M. Y. et al. NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119, 803–814 (2004).

  32. 32

    Parent, M. et al. Poly(ADP-ribose) polymerase-1 is a negative regulator of HIV-1 transcription through competitive binding to TAR RNA with Tat-positive transcription elongation factor b (p-TEFb) complex. J. Biol. Chem. 280, 448–457 (2005).

  33. 33

    Sawaya, B. E. et al. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J. Biol. Chem. 275, 35209–35214 (2000).

  34. 34

    Kashanchi, F. et al. Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J. Virol. 74, 652–660 (2000).

  35. 35

    Zong, W.X. et al. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18, 1223–1226 (2004).

Download references


PARP-1 expression vector was generously provided by Z.-Q. Wang (IARC, Lyon, France) and p65/RelA expression constructs were gifts from D.R. Green (La Jolla Institute for Allergy and Immunology, San Diego, CA). We thank M.A. Chattergoon and D.J. Laddy for their useful comments, and M.J. Merva for administrative assistance. Support from the National Institutes of Health (NIH) AIDS Research and Reference Reagents program and Centers for AIDS Research (CFAR), University of Pennsylvania, is also acknowledged. This work was supported by grants from the NIH to D.B.W.

Author information

Correspondence to David B. Weiner.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

Supplementary Figures S1, S2 and S3 (PDF 313 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading